Henry G. Grabowski
Professor Emeritus of Economics
Professor Grabowski specializes in the investigation of economics in the pharmaceutical industry, government regulation of business, and the economics of innovation. His specific interests within these fields include intellectual property and generic competition issues, the effects of government policy actions, and the costs and returns to pharmaceutical R&D. He has been publishing research papers for over four decades, from his earlier work, “The Effects of Regulatory Policy on the Incentives to Innovate: An International Comparative Analysis” with John Vernon and Lacy Glenn Thomas, to his more recent projects including, “Impact of Economic, Regulatory and Patent Policies on Innovation in Cancer Chemoprevention” with Jeffrey L. Moe. His latest research studies include other such titles as, “Mergers and Alliances in Pharmaceuticals: Effects on Innovation and R&D Productivity” with Margaret Kyle; “Should the Patent System for New Medicines Be Abolished?” with J.A. DiMasi; and several others. Professor Grabowski has served as an advisor and consultant to various organizations, offering his ideas and insights gained through his extensive investigations to the National Trade Academy of Sciences, the Institute of Medicine, the Office of Technology Assessment, the Federal Trade Commission, and the General Accounting Office. His latest project involved an analysis for the FTC concerning public policy, competition and investment in the “Next Generation of Biologics.”
- Ph.D., Princeton University 1967
- M.A., Princeton University 1964
- B.S., Lehigh University 1962
Grabowski, Henry G., Zoya Marriott, Penka Kovacheva, and Andrew Elzinga. “One Year after the Launch of the First U.S. Biosimilar Drug: Lessons for the Future?,” August 9, 2017.
Skinner, Mark W., P Ann Hedlund Hoppe, Henry G. Grabowski, Richard Manning, Raffi Tachdjian, James F. Crone, and Stuart J. Youngner. “Risk-based decision making and ethical considerations in donor compensation for plasma-derived medicinal products..” Transfusion 56, no. 11 (November 2016): 2889–94. https://doi.org/10.1111/trf.13764. Full Text Open Access Copy
Grabowski, Henry, Genia Long, Richard Mortimer, and Ani Boyo. “Updated trends in US brand-name and generic drug competition.” Journal of Medical Economics 19, no. 9 (September 2016): 836–44. https://doi.org/10.1080/13696998.2016.1176578. Full Text Open Access Copy
Grabowski, H. G., and R. L. Manning. “An Economic Analysis of Global Policy Proposals to Prohibit Compensation of Blood Plasma Donors.” International Journal of the Economics of Business 23, no. 2 (May 3, 2016): 149–66. https://doi.org/10.1080/13571516.2016.1182690. Full Text Open Access Copy
DiMasi, Joseph A., Henry G. Grabowski, and Ronald W. Hansen. “Innovation in the pharmaceutical industry: New estimates of R&D costs..” Journal of Health Economics 47 (May 2016): 20–33. https://doi.org/10.1016/j.jhealeco.2016.01.012. Full Text Open Access Copy
Lietzan, Erika Fisher, and Henry G. Grabowski. “FDA Regulation of Biosimilars,” September 16, 2015.
DiMasi, Joseph A., Henry G. Grabowski, and Ronald W. Hansen. “The cost of drug development..” The New England Journal of Medicine 372, no. 20 (May 2015). https://doi.org/10.1056/nejmc1504317. Full Text Open Access Copy
Grabowski, Henry G., Joseph A. DiMasi, and Genia Long. “The roles of patents and research and development incentives in biopharmaceutical innovation..” Health Affairs (Project Hope) 34, no. 2 (February 2015): 302–10. https://doi.org/10.1377/hlthaff.2014.1047. Full Text Open Access Copy
Grabowski, Henry G., Rahul Guha, and Maria Salgado. “Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future..” Health Affairs (Project Hope) 33, no. 6 (June 2014): 1048–57. https://doi.org/10.1377/hlthaff.2013.0862. Full Text Open Access Copy
Grabowski, H. G., G. Long, and R. Mortiner. “Biosimilars.” In Encyclopedia of Health Economics, edited by A. Culyer, Vol. 1. Elsevier, 2014.
DiMasi, J. A., and H. G. Grabowski. “R&D Costs and Returns to New Drug Development: A Review of the Evidence.” In The Oxford Handbook of the Economics of the Biopharmaceutical Industry, 2012. https://doi.org/10.1093/oxfordhb/9780199742998.013.0002. Full Text Open Access Copy
Grabowski, H. G., and M. Kyle. “Mergers, Acquisitions, and Alliances.” In The Oxford Handbook of the Economics of the Biopharmaceutical Industry, 2012. https://doi.org/10.1093/oxfordhb/9780199742998.013.0018. Full Text Open Access Copy
Grabowski, H. G. “The Contribution of the United States, Europe and Japan in Discovering New Drugs: 1982-2003.” In Incentives for Research, Development, and Innovation in Pharmaceuticals, edited by Walter A. Garcia-Fontes, 49–68. Springer, 2012. Open Access Copy
Grabowski, H. G., H. G. Ridley, David B., and H. G. Moe, Jeffrey L. “Encouraging innovative treatment of neglected diseases through priority review vouchers.” In Prescribing Cultures and Pharmaceutical Policy in the Asia-Pacific, edited by Karen Eggleston, 347–65. Stanford, CA: Stanford University: The Walter H, Shorenstein Asia-Pacific Research Center, 2009. Open Access Copy
Grabowski, H. G., and Margaret Kyle. “Mergers and Alliances in Pharmaceutical: Effects on Innovation and R&D Productivity.” In The Economics of Corporate Governance and Mergers, edited by K. Gugler and B. Yurtoglu, 262–87. Cheltenham, UK; USA: Edward Elgar Publishing, 2008. Open Access Copy
Grabowski, H. G. “Competition between Generic and Branded Drugs.” In Pharmaceutical Innovation: Incentives, Competition, and Cost-Benefit Analysis in International Perspective, edited by Frank A. Sloan and Chee-Ruey Hsieh, 153–288. Cambridge; New York: Cambridge University Press, 2007. Open Access Copy
Grabowski, H. G. “Increasing R&D Incentives for Neglected Diseases: Lessons from the Orphan Drug Act.” In International Public Goods And Transfer Of Technology Under A Globalized Intellectual Property Regime, edited by Keith Keith Eugene Maskus and J Jerome H. Reichman, 457–80, 2005. Open Access Copy
Grabowski, H. G. “Increasing R&D incentives for neglected diseases: Lessons from the Orphan Drug Act.” In International Public Goods And Transfer Of Technology Under A Globalized Intellectual Property Regime, edited by Keith Keith Eugene Maskus and J Jerome H. Reichman, 457–80. Cambridge, UK, New York: Cambridge University Press, 2005. Open Access Copy